Literature DB >> 23372150

Haplo-BMT: which approach?

Andrea Velardi1.   

Abstract

In patients with hematologic malignancies, Di Bartolomeo et al report encouraging outcomes after transplantation of granulocyte-colony stimulating factor (G-CSF)– primed unmanipulated bone marrow from human leukocyte antigen (HLA)– haplotype mismatched (haploidentical) related donors, suggesting that this procedure makes haploidentical transplantation available in all transplant centers.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23372150     DOI： 10.1182/blood-2012-12-469981

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  4 in total

1.  T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis.

Authors:  Norbert-Claude Gorin; Myriam Labopin; Simona Piemontese; William Arcese; Stella Santarone; He Huang; Giovanna Meloni; Felicetto Ferrara; Dietrich Beelen; Miguel Sanz; Andrea Bacigalupo; Fabio Ciceri; Audrey Mailhol; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

Review 2.  Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

3.  A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.

Authors:  M Labopin; N-C Gorin; E Polge; G Socié; G Gurman; E Gluckman; P Jindra; X Poiré; K Schäfer-Eckart; T Ruutu; G Milone; W Arcese; M Mohty; V Rocha
Journal:  Bone Marrow Transplant       Date:  2013-11-18       Impact factor: 5.483

Review 4.  T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease.

Authors:  Antonio Pierini; Loredana Ruggeri; Antonella Mancusi; Alessandra Carotti; Franca Falzetti; Adelmo Terenzi; Massimo Fabrizio Martelli; Andrea Velardi
Journal:  Bone Marrow Transplant       Date:  2019-08       Impact factor: 5.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.